Humana Inc. entered into a national coverage agreement with Plus Therapeutics’ CNSide Diagnostics for the CNSide CSF Tumor Cell Enumeration (TCE) laboratory‑developed test. The agreement, effective October 29 2025, extends coverage to roughly 67 million people across the United States, including Medicare Advantage and commercial members. The CNSide TCE test detects tumor cells in cerebrospinal fluid with 92 % sensitivity and 95 % specificity, enabling earlier diagnosis and treatment monitoring for patients with leptomeningeal metastases.
For Humana, the deal adds a high‑margin diagnostic service to its CenterWell portfolio, creating a new fee‑for‑service revenue stream while reinforcing the company’s precision‑oncology strategy. By offering the CNSide test nationwide, Humana can provide members with advanced care options that improve clinical outcomes and differentiate its health plans in a competitive market.
For Plus Therapeutics, the national coverage agreement represents a critical step in commercializing the CNSide test. The expanded coverage to 67 million people dramatically increases potential utilization and revenue, while the partnership with a major insurer validates the test’s clinical utility and positions the company for broader adoption of its CNSide platform and related therapeutics.
Humana’s Q3 2025 results show adjusted earnings of $3.24 per share and revenue of $32.65 billion, a modest revenue beat and an EPS beat of $0.41. The company reaffirmed its full‑year 2025 adjusted EPS guidance of approximately $17.00, indicating confidence in continued growth. The new diagnostic partnership is expected to contribute to the fee‑for‑service income that underpins Humana’s earnings outlook.
Plus Therapeutics reported a Q3 2025 net loss of $4.42 million and cash and investments of $16.6 million as of September 30 2025. The national coverage agreement is anticipated to accelerate revenue generation and improve the company’s cash runway, supporting its ongoing development of CNSide‑based therapeutics and other oncology products.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.